Junior Accountant Consultant
Boost your chances before you apply.
Scilex Holding
Palo Alto, CA, US
Summary
The Junior Accountant Consultant will manage accounts receivable, perform account reconciliations, and handle daily cash management duties. They will also assist with month-end close procedures, prepare financial reports, and support the annual audit process.
Job Description
$35.00 per hour up to 40 hours per week, eligible for health insurance and 401(k) benefits.
Role and Responsibilities:
- Maintain accounts receivable records to ensure aging is up to date, credits and collections are applied, uncollectible amounts are accounted for, and miscellaneous differences are cleared.
- Maintain and reconcile customer accounts, set up new customers and credit limit.
- Perform daily cash management duties, including the recording of bank deposits, wire/ACH payments, and posting of cash to the AR sub-ledger.
- Monitor and collect accounts receivable by contacting customers via telephone and email.
- Download gross sales report from 3PL system and import it to NetSuite using csv import.
- Prepare invoices and AR payment deductions journal entries for chargeback, chargeback rejection, return and service fees.
- Prepare AR weekly reports.
- Prepare monthly inventory adjustments and inventory accounts reconciliation.
- Analyzes, researches, and reconciles past payments.
- Maintains and reconciles A/R aging reports, check registers, and A/R journals.
- Responsible for Accounts Receivable month-end close procedures such as cash discounts and credit card fees journal entries.
- Prepare journal entries, account reconciliations and fluxes as part of month/quarter/year end reporting.
- Assist Management with various special projects and ad hoc reporting.
- Assist with preparation of documentation for the annual audit.
Qualifications and Education Requirements:
- Candidates should be in their senior year of college or recent graduates with a bachelor's or above in Accounting.
- Proficient in Microsoft Outlook, Word, Excel and NetSuite preferred.
Preferred Skills:
- Demonstrated written and verbal communication.
- Knowledge of automated financial systems.
- Strong integrity and professionalism.
- Good judgment and experience in solving problems.
- Ability to contribute to and work within a cross-functional team.
- Ability to work effectively in a fast-paced environment with multiple deadlines and frequently changing priorities.
- Must possess the ability to take initiative to complete assignments and job responsibilities with minimal supervision.
- Highly organized with a strong attention to detail, clarity, accuracy, and conciseness.
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief. Click here for ZTLido’s Important Safety Information and US Prescribing Information.
We have acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in 2023 and launched and began commercializing GLOPERBA® in 2024.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to patients who need them the most.
Our pipeline product candidates are
(i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain;
(ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido®, has recently completed a Phase 2 trial in acute lower back pain ;
Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
Founded
2019
Company size
51-200 employees
Industry
Pharmaceutical Manufacturing
Org type
Public Company
Headquarters
Palo Alto, California
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief. Click here for ZTLido’s Important Safety Information and US Prescribing Information.
We have acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in 2023 and launched and began commercializing GLOPERBA® in 2024.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to patients who need them the most.
Our pipeline product candidates are
(i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain;
(ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido®, has recently completed a Phase 2 trial in acute lower back pain ;
Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
Founded
2019
Company size
51-200 employees
Industry
Pharmaceutical Manufacturing
Org type
Public Company
Headquarters
Palo Alto, California